Bicara Therapeutics Inc. Common Stock (BCAX) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Zero revenue ⢠Heavy cash burn BCAX has a very strong cash/investment buffer and negligible leverage but no revenue and persistent heavy cash burn driving sustained operating and net losses.
Price Behavior
Key Price Behavior Insights: ⢠Fresh breakout ⢠Extended above mean ⢠Pullback risk Support Level: $20.06â$20.50; $18.40 Resistance Level: $20.06â$20.50 (recently broken) BCAX has broken above prior resistance and is in a clear short-term uptrend after a ~16% rally since 2026-03-05, but the move is extendedâabout 12% above its last month averageâleaving it vulnerable to a pullback to the $20.06â$20.50 zone (now near-term support) or deeper toward ~$18.40.
Sentiment & News
Key News Insights: ⢠Phase 3 start ⢠Dose optimization ⢠Analyst bullishness Bicara advanced ficerafusp alfa into a 1,500 mg weekly Phase 3 regimen with a Q2â2027 interim readout, rolled out lessâfrequent dosing options, drew stronger analyst optimism and share gains, and revealed insider sales amid nearâterm ASCO and pivotal milestones.
AI Summary
BCAX has shifted into a milestoneâdriven singleâasset Phaseâ3 story where the midâ2027 interim readout (and current cash buffer) now dominate upside, so investors should size exposure around the trial timeline and treat upcoming enrollment/readout cadence as the primary catalyst. Monitor enrollment speed, burn versus runway, and the interim efficacy/safety signalâdelays or negative results would likely force dilution and compress valuation, while a positive readout could trigger reârating or partnering interest.
Description
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody that combines an EGFR-targeting monoclonal antibody with a domain that binds TGF-β. Founded in 2018 and based in Boston, the company is a subsidiary of Biocon Limited.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 19 | Mar 26 | BCAX | Bicara Therapeutics Inc. Common Stock | BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term. | Closed | +0.7% |